Assenagon Asset Management S.A. Cuts Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Assenagon Asset Management S.A. lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 54.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 730,820 shares of the biopharmaceutical company's stock after selling 856,897 shares during the quarter. Assenagon Asset Management S.A. owned about 1.27% of Vanda Pharmaceuticals worth $3,004,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Barclays PLC grew its holdings in Vanda Pharmaceuticals by 2.6% in the third quarter. Barclays PLC now owns 128,330 shares of the biopharmaceutical company's stock worth $554,000 after purchasing an additional 3,265 shares during the period. Swiss National Bank grew its holdings in shares of Vanda Pharmaceuticals by 3.4% during the third quarter. Swiss National Bank now owns 126,300 shares of the biopharmaceutical company's stock valued at $546,000 after buying an additional 4,100 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 5,186 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Vanda Pharmaceuticals by 57.1% during the third quarter. New York State Common Retirement Fund now owns 17,805 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 6,470 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Vanda Pharmaceuticals by 13.7% during the third quarter. Public Employees Retirement System of Ohio now owns 75,648 shares of the biopharmaceutical company's stock valued at $327,000 after buying an additional 9,100 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Down 3.8 %

VNDA stock traded down $0.21 on Monday, hitting $5.27. The company had a trading volume of 685,390 shares, compared to its average volume of 1,930,244. Vanda Pharmaceuticals Inc. has a 12-month low of $3.30 and a 12-month high of $6.76. The stock's 50-day simple moving average is $4.51 and its 200 day simple moving average is $4.15. The stock has a market cap of $306.71 million, a price-to-earnings ratio of -65.88 and a beta of 0.71.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on VNDA. TheStreet cut shares of Vanda Pharmaceuticals from a "c-" rating to a "d" rating in a report on Thursday, February 8th. StockNews.com cut shares of Vanda Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, April 22nd.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.